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Abstract The binding of the transcription factor AP-I to DNA 
has been shown to be modulated by redox control mechanisms. 
Selenite and selenodiglutathione (GS-Se-SG), inhibit mammalian 
cell growth and are efficient oxidants of reduced thioredoxin and 
reduced thioredoxin reductase. Here, we report that selenite and 
GS-Se-SG efficiently inhibited AP-I DNA-binding in nuclear 
extracts from 3B6 lymphocytes. A GS-Se-SG concentration of 
0.75 /tM resulted in 50% inhibition of AP-1 DNA-binding, 
whereas the same effect was achieved with 7.5 /xM selenite. 
Nuclear extracts prepared from human 3B6 lymphocytes exposed 
for 4 h to 10 ~M selenite showed a 50% reduction of AP-I 
binding. These data suggest hat selenite and selenodiglutathione 
inactivate the AP-1 factor and provide a mechanism by which 
selenium compounds inhibit cell growth. 
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1. Introduction 
The protein products, Fos and Jun, of the proto-oncogene 
families c-fos and c-jun are components of the transcription 
factor AP-1 [1]. AP-1 binds to and activates transcription from 
the TPA-responsive element (TRE) (TGAC/GTCA). Although 
the AP-1 binding site was originally defined as a phorbol ester- 
responsive lement, it is present in the promoter of genes impli- 
cated in a number of signal transduction cascades associated 
with growth, neuronal excitation, cellular stress, transforma- 
tion and differentiation suggesting a central role for AP-1 in 
signal transduction [2,3]. Jun proteins can form homodimers or 
heterodimers among themselves, but more readily dimerize 
with the Fos proteins (including c-Fos, Fos-B, Fra-1, and Fra- 
2) which do not form dimers among themselves. Dimers are 
formed through a coiled-coil interaction involving leucine zip- 
per domais in each protein [4]. All of the Jun/Jun and Jun/Fos 
complexes probably have identical DNA binding specificities 
but different binding affinities as measured in vitro [5]. DNA- 
binding is mediated through juxtaposition of conserved basic 
regions of each protein in the heterodimer. DNA binding of 
endogenous AP-1 complexes i regulated through post-transla- 
tional modifications including both phosphorylation and 
dephosphorylation [6-8]. In addition to phosphorylation, re- 
duction-oxidation (redox control) also regulates the DNA 
binding activity of AP-1 in vitro [9,10]. The redox-status of two 
conserved cysteine residues (Fos-Cys-154 and Jun-Cys-272) in 
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the heterodimer is important for DNA binding although they 
do not directly participate in the binding. Reduced cysteine 
residues leads to enhanced DNA-binding whereas oxidation 
inhibits binding [9]. A protein (Ref-1) has been isolated that 
enhances binding via reduction of the oxidized cysteine residues 
[10]. 
Thioredoxin (12 kDa), in its oxidized form, has a redox- 
active disulfide on a protrusion in the three-dimensional struc- 
ture, and is reduced by thioredoxin reductase and NADPH (the 
thioredoxin system) [11-13]. The dithiol in reduced thioredoxin 
is a powerful general protein disulfide reductase [14]. ADF 
(adult T-cell leukemia derived factor) is secreted human thiore- 
doxin and operates as a cytokine [15]. The thioredoxin system 
enhances the binding of Fos/Jun to DNA via reduction of Ref-1 
[10]. 
Selenium is an essential trace element in higher eukaryotes 
[16] but also very toxic. Selenium compounds have well-docu- 
mented inhibitory effects on mammalian cell-growth [17,18]. 
Low levels (nM) of sodium selenite stimulate cell-growth and 
selenite is an essential component of serum-free media [19]. The 
most established function of selenium is its presence as a se- 
lenocysteine r sidue in glutathione peroxidase. This enzyme is 
important for the detoxification of hydrogen peroxide, lipid 
hydroperoxides and organic hydroperoxides [20]. However, 
changes in the function and levels of glutathione peroxidase do 
not seem to be directly involved in the effects of selenium 
compounds on cell growth [21]. Selenite is a potent oxidant of 
thiols and a direct substrate for mammalian thioredoxin and 
thioredoxin reductase [22]. In mammalian tissues selenite is 
believed to react with reduced glutathione (GSH) to form selen- 
odiglutathione GS-Se-SG [23]. This compound can undergo 
further eduction by the thioredoxin system [24] or glutathione 
reductase [25]. GS-Se-SG is an oxidant of thiols and kinetically 
one of the most efficient substrates known for reduced thiore- 
doxin [24]. Furthermore, GS-Se-SG efficiently inhibits human 
thioredoxin through oxidation of Cys-72 [26], a structural cys- 
teine residue located close to the active site [13]. Incubation of 
GS-Se-SG or selenite with mammalian thioredoxin reductase 
leads to redox-cycling with oxygen and a large nonstoichiomet- 
ric oxidation of NADPH [22,24]. 
The aim of the present study was to investigate whether 
selenite and GS-Se-SG could inhibit Fos/Jun-binding via oxida- 
tion. An inhibitory effect of selenium on the activity of onco- 
gene products could be an important mechanism in explaning 
the inhibitory effects of selenium compounds on cell-growth. 
2. Experimental 
2.1. Materials 
GS-Se-SG was prepared as described by Bj6rnstedt, et al. [24]. Re- 
combinant human thioredoxin was prepared as described by Ren et al, 
[26] and human thioredoxin reductase was prepared from placenta 
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essentially as described by Luthman and Holmgren [27]. The prepara- 
tion was of better than 90% purity. RPMI medium was from Flow 
Laboratories (Ayshire, UK) and fetal calf serum, glutamine and antibi- 
otics were from GIBCO Ltd., UK. The double strand AP-1 oligonucle- 
otide and the CytoTox 96 non-radioactive cytotoxicity assay were ob- 
tained from Promega. All other chemicals were from Sigma. Specific 
anti-Jun rabbit polyclonal antibodies were generated by immunization 
with synthetic peptides coupled to keyhole limpet hemocyanin. The 
peptides used were: c-Jun, SYGAAGLAFPSQPQQ; JunB,ISYLPHA- 
PPFAGG; and JunD, GCQLLPQHQVPAY. No cross-reactivity was 
observed between the different antisera [28]. 
2.2. Cell culture conditions 
The EBV-transformed lymphoblastoid cell-line 3B6 was kindly pro- 
vided by Professor T. Tursz, Inst. Gustave-Roussy, Paris, France. The 
cells were grown in RPMI supplemented with 10% (v/v) fetal calf serum, 
glutamine and antibiotics, in 5% CO2 atmosphere. Cultures with a 
density of 0.5 x 10 6 cells/ml were used for nuclear extract preparation. 
2.3. Preparation of nuclear extracts" 
Nuclear extracts were prepared according to a modified version of 
a previously described method [29]. Briefly, cells were washed twice 
with ice-cold phosphate-buffered saline, pelleted, and then gently resus- 
pended in 200/~1 of a buffer composed of 15 mM Tris-HC1, pH 7.5, 0.5 
M sucrose, 60 mM KC1, 0.25 mM EDTA, 0.5 mM spermidine, 2 mM 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1 pg/ml aprotinin, 
and 1/~g/ml pepstatin. Cells were allowed to swell on ice for 20 rain, 
then 10 pl of a 10% solution of NP-40 was added, and the tube was 
vigorously vortexed for 10 s. After centrifugation for 5 min at 6,500 rpm 
in an Eppendorf centrifuge, the supernatant was removed and the 
nuclear pellet was resuspended in 150/.tl of 20 mM HEPES, pH 7.9, 25% 
glycerol, 0.4 M NaCI, 0.25 mM EDTA, 1.5 mM MgCI2, 0.5 mM phen- 
ylmethylsulfonyl fluoride, 1 /.tg/ml leupeptin, 1 /lg/ml aprotinin, and 
1/lg/ml pepstatin. The samples were shaken vigorously at 4°C for 25 
min, then centrifuged for 30 min and the supernatant was frozen in 
aliquots. Protein was determined by the method of Bradford. 
2.4. In vitro transcription and translation 
Mouse JunB/c-Fos was synthesized in vitro by transcription of 
mouse junB and c-fos cDNA by using T7 RNA polymerase and subse- 
quent cotranslation i a rabbit reticulocyte translation system (Amer- 
sham). In vitro translation was performed according to the manufac- 
turer's instructions. 
2.5. Gel retardation analysis" 
Gel shift analysis was performed with 4/~g of extract protein. Ex- 
tracts were preincubated in the presence or absence of selenium com- 
pounds for 10 min at room temperature. A binding buffer, (0.2 ~g of 
poly(dI-dC) and 1.5 Jtg of sonicated salmon sperm DNA in 20 mM 
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Fig. 1. Gel shift analysis ofAP-1 DNA-binding activity in 3B6 nuclear 
extracts. The 3ZP-labelled AP-1 specific oligonucleotide was incubated 
with 4/lg of 3B6 nuclear extracts which had been preincubated with 
different antisera for 30 min at 4°C. The generation and the specificity 
of the antisera to c-Jun, JunB and JunD are described in section 2. 
Preimm denotes extracts preincubated with rabbit preimmune serum. 
The positions of the free oligonucleotide (open arrowheads) and the 
retarded protein-DNA complex (filled arrowheads) are indicated. 
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Fig. 2. Inhibition of AP-1 DNA-binding by selenite and selenodiglu- 
tathione. Nuclear extracts (4 pg) of 3B6 cells were incubated in the 
presense of oxidized glutathione (GSSG), selenodiglutathione (GS-Se- 
SG), selenite (SeO~3-) and selenate (SeO24 -) at the indicated concentra- 
tions in a total volume of 10/11 for l 0 min at room temperature. Binding 
buffer (25 ~1) was added for 15 min before the addition of the 32p_ 
labelled AP-1 oligonucleotide. The values at the bottom of the figure 
are percent of counts in the AP-1 complex, compared to control extracts 
and were obtained by phosphoimager analysis. 
HEPES, 0.1 mM EDTA, 12% glycerol, 4 mM MgC12, 4 mM spermid- 
ine, and 0.1 mg/ml bovine serum albumin) was added to each sample 
and the samples were stored on ice for 15 min. The labelled probe was 
added and the samples were incubated at room temperature for 15 min. 
The resulting protein-DNA complexes were resolved from unbound 
oligonucleotides on a pre-electrophoresed polyacrylamide gel (29: 1) 
with 0.25 x TBE (1 x TBE: 90 mM Tris-borate pH 8, 1 mM EDTA) as 
running buffer. Gels were fixed in 10% acetic acid, 10% methanol, dryed 
and visualized by autoradiography. Quantification was done with the 
Molecular Dynamics Phosphoimager. The double-stranded AP-1 ol- 
igonucleotide used as probe (factor binding site underlined) (5'- 
CGCTTGATGAGTCAGCCGGAA-3'/3'-GCGAACT ACTCAGTC- 
GGCCTT-5') was labelled with [32P]ATP by T4 polynucleotide kinase 
from Pharmacia. 
3. Resul~ and discussion 
We examined the binding of factors present in the nuclear 
extracts from human 3B6 lymphocytes to a labeled synthetic 
double stranded AP-I  oligonucleotide probe using gel shift 
analysis. Specific antibodies were used to determine the type of 
Jun protein present in the AP-1 complexes that gave binding 
to the AP-1 consensus element (Fig. 1). A clear decrease in the 
intensity of the retarded band was observed when the antiserum 
specific to JunB was added (Fig. 1). In contrast, the anti-c-Jun 
and ant i - JunD antibodies did not significantly alter the inten- 
sity of the bound complex. Thus, in the 3B6 cells, JunB was the 
predominant Jun component. 
Treatment of nuclear extracts with selenite and GS-Se-SG for 
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10 min at room temperature, before addition of binding buffer 
and the 32p-labelled AP-1 oligonucleotide, inhibited AP-1 DNA 
binding (Fig. 2). The concentration f selenite required for 50% 
inhibition of binding was 7.5/.tM. The natural selenium etab- 
olite GS-Se-SG was far more efficient at inhibition. Only 0.75 
gM was required to obtain the same result as with 7.5/sM 
selenite. In contrast selenate at a much higher concentration 
(250/IM) had only a small inhibitory effect. Also, oxidized 
glutathione (GSSG), at 100/.tM inhibited to a very limited 
extent (Fig. 2) demonstrating the dramatic effect by the pres- 
ence of a Se atom between the sulfurs in glutathione disulfide. 
Since JunB was the major Jun component of the AP-1 factor 
in the 3B6 cells, we used a rabbit reticulocyte lysate system to 
cotranslate JunB and c-Fos. Addition of selenite and GS-Se-SG 
to in vitro translated JunB/c-Fos also resulted in efficient inhi- 
bition (Fig. 3). Total inhibition was obtained by 1 ~M of selen- 
ite or 1 ~M of GS-Se-SG. In accordance with previous reports, 
DTT stimulated AP-1 DNA binding of nuclear extracts [9]. The 
presence of DTT also prevented the effect of selenite in a con- 
centration dependent manner (Fig. 4). This clearly showed that 
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Fig. 3. The DNA-binding activity of in vitro translated JunB/c-Fos is 
inhibited by selenite and selenodiglutathione. I  vitro co-translation f 
JunB and c-Fos in rabbit reticulocyte lysate was carried out in the 
presense ofin vitro synthesized junB and c-fos mRNAs. In vitro trans- 
lated JunB/c-Fos (1/.tl) was incubated with selenite, selenodiglutathione 
and binding buffer for 10 min at room temperature in a total volume 
of 30 gl. The 32P-labelled AP-I oligonucleotide was added for 15 min 
at room temperature and the samples were analyzed by gel electropho- 
resis. 
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Fig. 4. Effect of DTT on selenite inhibition of DNA binding. Nuclear 
extracts were incubated for 10 min at room temperature with 50/.tM 
selenite or without (control) using DTT at 50, 250, and 500 gM, respec- 
tively. The gel retardation assay was performed as outlined in the legend 
to Fig. 2. 
the inhibitory effects of selenite was mediated by a redox mech- 
anism. Thioredoxin is known to stimulate AP-1 DNA binding 
through reduction of the Ref-1 protein present in the nuclear 
extracts [10]. We found that addition of thioredoxin, thiore- 
doxin reductase and NADPH (the thioredoxin system) stimu- 
lated binding by 60% (Fig. 5). The presence of the thioredoxin- 
system could only partly prevent the inhibitory effect of selenite 
(Fig. 5). 
Fos and Jun are regulated by the redox status of a single 
conserved cysteine residue. Reduction enhances binding 
whereas oxidation inhibits binding. The mechanism behind the 
oxidative inhibition is so far not certain, since mutagenesis of 
the cysteines has revealed that oxidation inhibits binding also 
when one of the cysteine residues in the heterodimer has been 
replaced by a serine [9]. This shows that inhibition is not de- 
pendent on the ability to form a disulfide bond within the 
heterodimer aswell as with other thiols. However, the cysteines 
can form disulfide bonds with SH groups of other cysteines 
from other heterodimers giving rise to slower migrating com- 
plexes upon oxidation. It has also been suggested that the 
formation of a cysteine sulfenic acid may play a role as shown 
in the case of OxyR [30]. 
To investigate if treatment of intact human lymphocytes with 
selenium compounds altered the AP-1 DNA binding activity, 
selenite or selenate was added to 3B6 cells. After incubation of 
the cells with selenite (10/IM) or selenate (250/.tM) for 4 h, 
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of the sulfhydryl groups of the reduced Ref-1 protein is also an 
alternative inhibitory mechanism of the selenium compounds. 
Selenite in high concentrations has been shown to react with 
thiols in proteins to form both -S-S- and -S-Se-S- bridges [31]. 
Upon exposure to selenite, Fos and Jun may form complexes 
connected by disulfides or -S-Se-S- bridges. Crosslinking of Fos 
and Jun with other protein thiols in the nuclear extract would 
also be possible. GS-Se-SG should contribute to complex for- 
mation more easily than selenite since only two electrons are 
needed to form the highly reactive selenopersulfide, GS-Se-. 
Further two electron reduction, will generate hydrogen se- 
lenide, which is known to redox-cycle with oxygen in the pres- 
ence of thiols. This is the most likely explaination of the more 
efficent inhibition by GS-Se-SG compared to selenite. 
We have shown that selenite and GS-Se-SG are potent inhib- 
itors of the AP-1 DNA binding activity. The AP-1 complex is 
an important transcription factor for the regulation of cell- 
growth and differentiation. Furthermore, many extracellular 
stimuli activate the AP-1 complex and mediate their stimula- 
tory effects via the AP-1 transcriptional ctivation. Selenium 
compounds have well documented inhibitory effects on cell 
growth and preventive effects for tumor promoter and carcino- 
genic substances [32,33]. The efficient inhibition of the AP-1 
DNA binding activity reported here should be an important 
% b ind ing]  160 71 43 100 [ 
Fig. 5. Effect of human thioredoxin reductase and thioredoxin on 
inhibition of AP-1 DNA-binding by selenite. Nuclear extracts were 
treated with selenite (50 gM) in the absence (-) or presence (+) of 0.04 
gM human placenta TR, 5 jIM Trx and 0.5 mM NADPH for 15 
min at room temperature in a total volume of 15 gl. Binding buffer 
was added and the samples were treated as described inthe legend to 
Fig. 2. 
nuclear extracts were prepared and AP-1 DNA binding was 
analyzed by gel-shift assays. The viability of the cells treated 
with selenite and selenate was comparable tocontrols as deter- 
mined by trypan blue exclusion and LDH releasing assays. The 
AP-1 DNA binding was decreased to 50% in the extracts from 
cells treated with selenite compared to control (Fig. 6). Selenate 
treatment did not inhibit AP-1 DNA-binding. The different 
concentrations u ed were based on unpublished observations 
(Spyrou, G., Bj6rnstedt, M., Skoog, S. and Holmgren, A., man- 
uscript in preparation) where cell-proliferation was completely 
inhibited by treatment with 10 gM sodium selenite and 250/2M 
sodium selenate for 24 hours. 
Selenite and GS-Se-SG are efficient oxidizing substrates of 
the thiols in thioredoxin or thioredoxin reductase and also 
operate as inhibitors of the mammalian thioredoxin system 
proteins [22-26]. Low concentrations of GS-Se-SG efficiently 
inhibit human thioredoxin by oxidation involving the structural 
Cys-72 [26]. Thus, interaction with the Cys-72 in thioredoxin 
could be one important mechanism for the inhibition of AP-l 
DNA binding in cells treated with selenite. By inhibition of 
thioredoxin, the Ref-1 protein cannot be reduced and oxidized 
Fos and Jun proteins cannot be reactivated. Direct oxidation 
SeO~-  - + -  
Se024 - + 
% binding[ lO0 54 98 ] 
Fig. 6. AP-1 DNA binding in 3B6 cells treated with selenite and sele- 
hate. Nuclear extracts werc prepared from 3B6 cells treated for 4 h with 
10/2M selenite or 250 gM selenate. Equal amounts of protein (4/2g) 
were incubated with binding buffer for 15 min on ice before the addition 
of the 32p-lahclled AP-I oligonucleotidc. 
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mechanism for explaining the inhibition of tumor cell growth 
and possibly blocking the effects of tumor promoters. 
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